People | April 29, 2026
NADMED Limited appoints James Lee as CEO to drive global expansion
Former Novo Nordisk and Pharmanovia executive to lead next growth phase in NAD diagnostics and personalised health innovation
Former Novo Nordisk and Pharmanovia executive to lead next growth phase in NAD diagnostics and personalised health innovation
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
Patients, doctors, and caregivers come together to promote awareness, early intervention, and pain-free living
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
In his new role, Gregory will drive partnerships for the company’s large-scale molecule biologics business across Europe
The approval was driven by data from the Phase III TULIP-SC trial
His appointment is expected to strengthen scientific input in policy discussions across public health, biotech, and translational research
India leads the shift as wellness tourism integrates healthcare, hospitality, and lifestyle
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
The move brings one of the country’s most widely prescribed blood thinners onto Cost Plus Drug Company’s online pharmacy platform
Subscribe To Our Newsletter & Stay Updated
